课题基金 / 基金详情

Cellular inhibitor of apoptosis 1 (cIAP1) as a novel therapeutic target for the treatment of Duchenne muscular dystrophy

Cellular inhibitor of apoptosis 1 (cIAP1) as a novel therapeutic target for the treatment of Duchenne muscular dystrophy
细胞凋亡抑制剂 1 (cIAP1) 作为杜氏肌营养不良症的新型治疗靶点
批准号:
412895
负责人:
Lala-Tabbert Neena
金额:
$9.83万
依托单位国家:
加拿大
项目类别:
Fellowship Programs
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-10-01 至 2022-10-01

项目摘要

项目成果

Lala-Tabbert Neena的其他基金

相似基金

相关文献

中文摘要
翻译
核因子-kB(NF-kB)通路形成信号传导复合物,其对于正常骨骼肌功能至关重要,并且在促进响应于肌肉损伤的恢复中是重要的。此外,有强有力的证据表明,过多的NF-kB活性,
英文摘要
The Nuclear Factor-kB (NF-kB) pathways form a signaling complex that is critical for normal skeletal muscle function and is important in promoting recovery in response to muscle injury. Furthermore, there is strong evidence that too much NF-kB activity is
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alternative NF-kB Signaling in Muscle Regeneration and Muscular Dystrophy
海外基金